Dr. Nandini Verma joined as a principal investigator at ACREC, TMC, after completing her post-doctoral training at the Moross Integrated Cancer Center (MICC), Department of Cell and Molecular Biology at the Weizmann Institute of Science, Israel. Dr. Verma earned her Ph.D. from Institute of Genomics and Integrated Biology (IGIB), New-Delhi, where she mostly worked on innate immune regulatory cellular signaling. During her post-doctoral research Dr. Verma discovered important cellular regulators of EGFR signaling in TNBC cells and mechanism of drug resistance in anti-EGFR targeted therapies. Her recent research work has uncovered novel subtype specific combination therapies for TNBC treatment.
Research Interest :